Zsuzsa Szombathyne Meszaros, MD, PhD, 315 464-5540

Zsuzsa Szombathyne Meszaros, MD, PhD
Appointed 08/14/06
330 Psychiatry and Behavioral Sciences Building
713 Harrison Street
Syracuse, NY 13210

315 464-5540

Current Appointments

Hospital Campus

  • Downtown

Research Programs and Affiliations

  • Psychiatry and Behavioral Sciences

Featured Video

Education & Fellowships

  • Additional Training: SUNY Upstate Medical University, 2008, Addiction Psychiatry Research
  • Residency: Tufts University, St. Elizabeth's Medical Center Campus, Boston, MA, 2007, Psychiatry
  • Fellowship: Semmelweis University, Budapest, Hungary, 1999, Clinical Pharmacology
  • PhD: Semmelweis Medical University, Budapest, Hungary, 1997, Pharmacology
  • MD: Semmelweis Medical University, Budapest, Hungary, 1994

Clinical Interests

  • Psychopharmacology
  • Schizophrenia
  • Alcohol and nicotine dependence
  • Psychiatric manifestations of lupus

Education Interests

  • Psychosomatic Medicine
  • Standardized Assessment
  • Motivational Interviewing

Research Interests

  • Smoking and alcohol use disorders commonly occur together.  People who drink alcohol are three times more likely to smoke, and smokers are four times more likely than the general population to be dependent on alcohol.  When nicotine and alcohol dependence occur together, the health risks are increased, and the chances of quitting smoking and drinking are lower.  The exact mechanism of co-occurring nicotine and alcohol dependence is not clearly understood.  In everyday clinical practice, interventions used for smoking cessation are not combined with treatment of alcohol dependence.  Our clinical research program is focused on developing new medications to treat alcohol and nicotine dependence simultaneously.  Two investigational new drugs recently tested at our division decreased drinking and/or smoking severity and prevented cognitive problems associated with smoking and drinking.  Our goal is to establish the safety and efficacy of these neuroprotective agents in different patient populations.  Preventing cognitive decline is of great importance to inpatients with addiction.  Development of new, neuroprotective medications may reduce harm associated with heavy smoking and alcohol use.

Specialties & Certification

  • Psychiatry

Diseases & Conditions Treated

  • Alcohol Use Disorder
  • Delirium
  • Dementia
  • Hallucinations
  • Mental Illness
  • Prescription Drug Abuse
  • Psychosis
  • Psychosomatic Illness
  • Schizophrenia


  • Adults


  • Diagnostic Assessment
  • Individual Psychotherapy
  • Outpatient Therapy and Medication Management
  • Psychopharmacology
  • Smoking Cessation

Languages Spoken (Other Than English)

  • Hungarian


Link to PubMed External Icon (Opens new window. Close the PubMed window to return to this page.)

Faculty Profile Shortcut: http://www.upstate.edu/faculty/meszaroz